Non-Hodgkin Lymphoma (NHL) is a type of cancer that affects B-cells, a type of white blood cell. This study is testing a new drug called epcoritamab to see if it's safe and how well it works when combined with other cancer-fighting drugs. Epcoritamab is given as a shot under the skin, and it will be combined with other drugs given either by mouth or through a vein. Different groups of people in the study will get different combinations of these drugs. Around 622 adults with NHL will join this study across 100 places worldwide.

Participants will receive treatment in cycles that may last 21, 28, or 56 days, depending on their group. They will visit a hospital or clinic regularly for check-ups, blood tests, and to report any side effects. The study might be more demanding than the usual care people with NHL receive.

• Participants will need to visit the study site regularly for check-ups.
• The study involves trying a new drug, which may have unknown risks.
• Participants may receive different combinations of treatment based on their group.